Society of Utah Medical Oncology

Welcome

Our primary mission is to promote the highest professional standards of oncology practice in the state of Utah; to study, research and exchange information, leading to improvement in the practice of hematology; to support and further oncology education; and to monitor and respond to appropriate legislative and regulatory concerns of the membership.

We encourage all oncology professionals to find out more about us and become a member of our growing community.

The Benefits of Membership

Become a member of the Society of Utah Medical Oncologists and enjoy these member only benefits:

  • Only professional organization that represents all hematology and oncology specialties and practices in Utah
  • Advocates on behalf of members on reimbursement and other issues
  • Provides a business meeting in the spring and a 1.5 day clinical meeting in the fall
  • Provides representation on legislative issues
  • Shares resources with other oncology-related organizations
  • Community outreach includes the University of Utah Oncology Interest Group for medical students
  • Acts as the institutional memory for the oncology community
  • Maintains a comprehensive database of member information
  • Collaborates with other state oncology societies, ASCO, COA, ASH and other entities as needed
  • Provides a comprehensive website
Join Today

CMS Open Payments: Review and Dispute Period Now Open
U.S. physicians have from April 1 until May 15 to review and dispute Open Payments data before it is made public on June 30. Review of the data is voluntary, but strongly encouraged to help improve the accuracy of the reported data.

Click here for more.

 

CMS Releases Final Hospital Outpatient Payment Rule - The Centers for Medicare and Medicaid Services (CMS) released the final CY 2019 Hospital Outpatient Prospective Payment System (OPPS) rule. In the Society’s comment letter, ASH requested that CMS change the status indicator for the four new Category III CPT codes for chimeric antigen receptor (CAR) T-cell therapy from “B” to “S.” In the final rule, CMS did finalize this change for one of the four codes, code 0540T, CAR-T cell administration, autologous. 

Click here for the report.

 

Upcoming Events


Register Now for 2019 Spring Meeting

2019 SUMO Spring Business Meeting 
April 23, 2019.
Salt Lake City Marriott City Center, 220 S State St, Salt Lake City, UT  84111.
Online Registration is closed now.
Click here for meeting information

 2019 SUMO Fall Meeting
September 27 -28, 2019
Hyatt Centric Park City, 3551 N Escala Ct, Park City, UT 84098

Don't miss out on the 2019 Best of ASCO Meetings

Two Days of Scientific Findings, Practice-Changing Discussion

The Best of ASCO Meetings condense the most cutting-edge science and education from the world’s premier oncology event, the ASCO Annual Meeting, into a two-day program. The abstracts chosen for presentation and discussion reflect the foremost research and strategies in oncology that will directly impact patient care.

Find out More here.

 

Denial Rates and Days to Pay for Cancer Drugs: Commercial Health Plan Report Card

Office-administered oncology drugs given in the community setting face stiff reimbursement challenges when billing commercial plans; while Medicare has emerged as the gold standard for both predictable payment and timeliness.

Click here for more.

 

8 Medicare and Medicaid reforms that would have the biggest impact on federal spending

Click here for more

Learn more about the big changes to the ASH Scholar Award program.
More people are now eligible for the ASH Scholar Awards than ever before. The new Fellow to Faculty Scholar Award offers financial support to those preparing to compete for independent faculty-level positions in the next two to three years.

Click here for more.